Adjuvant Rituximab—Exploratory Trial in Young People With Graves Disease

CONTEXT: Remission rates in young people with Graves hyperthyroidism are less than 25% after 2 years of thionamide antithyroid drug (ATD). OBJECTIVE: We explored whether rituximab (RTX), a B-lymphocyte–depleting agent, would increase remission rates when administered with a short course of ATD. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheetham, Tim D, Cole, Michael, Abinun, Mario, Allahabadia, Amit, Barratt, Tim, Davies, Justin H, Dimitri, Paul, Drake, Amanda, Mohamed, Zainaba, Murray, Robert D, Steele, Caroline A, Zammitt, Nicola, Carnell, Sonya, Prichard, Jonathan, Watson, Gillian, Hambleton, Sophie, Matthews, John N S, Pearce, Simon H S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851941/
https://www.ncbi.nlm.nih.gov/pubmed/34687316
http://dx.doi.org/10.1210/clinem/dgab763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851941/
https://www.ncbi.nlm.nih.gov/pubmed/34687316
http://dx.doi.org/10.1210/clinem/dgab763

Ejemplares similares